Meeting Banner
Abstract #0864

Early Perfusion Changes in Patients with Recurrent Low-Grade Gliomas Treated with Everolimus (RAD001) Under a Phase II Clinical Trial

Michael Wahl1, Christopher Kazu Williams2, Janine Lupo2, Susan Chang3, Daphne Haas-Kogan1, Sarah Nelson2, 4

1Radiation Oncology, University of California, San Francisco, San Francisco, CA, United States; 2Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States; 3Neurosurgery, University of California, San Francisco, San Francisco, CA, United States; 4Bioengineering and Theraputic Sciences, University of California, San Francisco, San Francisco, CA, United States

Everolimus is an inhibitor of mTOR, a molecule in a signaling pathway activated in most low-grade gliomas and known to have angiogenic effects. In this phase II clinical trial, patients with recurrent low grade gliomas are treated with everolimus and followed with serial multimodal MRI while on treatment. We observe a significant decrease in DCE perfusion MRI parameters, including FBV (a measure of capillary density) and Kps (a measure of vascular permeability). This represents the first clinical demonstration of antiangiogenic effects of everolimus, and raises the possibility that perfusion parameters can be used as early markers of treatment response.

Abstract PDF Poster PDF

Keywords

activation addition adverse alterations anisotropy apparent appearing assess asterisks benefit bioengineering biomedical blood bottom brain cancer capillary cell choline clinical coefficient computed contrast decrease decreased defined demonstration denoted density derived determine diffusion disease dropped dynamic early enhanced enhancing established every example expanded experience experienced experimental extent five flair fractional frequently generated grade grant growing heights index inhibitor inhibitors knowledge lactate lane lesion lesions lipid longer manually maps marker markers measurable measured median months needed nelson neurosurgery normalized observe oncology pathway patients peak percentile perfusion permeability possibility predictive primary progressing progression properties radiation radiology raising rank recent recur recurrent reductions represent respectively response sciences serial setting side signed significantly similarly slow specifically spectroscopic spore stable start studies subject subjects supported surgical therapy thirteen tissues treated treatment trial tumor tumors undergoing vascular volume volumes whether white